SCHEMBL15599600

SCHEMBL15599600

CC(C)(C)OC(=O)NC1CCC(n2c(=O)oc3ccccc32)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.49
PARP1 P09874 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
OGFRL1 Q5TC84 1/20 0.47
KDM1A O60341 1/20 0.47
MAOB P27338 1/20 0.47
HSD11B1 P28845 1/20 0.46
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
DRD2 P14416 2/20 0.44
PLD1 Q13393 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
NPY5R Q15761 1/20 0.43
PIK3CA P42336 1/20 0.42
MTOR P42345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15575356 0.82 TNKS (0.57) TNKSPARP1PARP2HSD11B1PLD1
SCHEMBL2606334 0.80 HSD11B1 (0.57) TNKSPARP1PARP2OPRM1OPRD1
SCHEMBL28522003 0.78 ALDH1A1 (0.56) TNKSPARP2OPRM1OPRD1OPRK1
SCHEMBL22605771 0.78 ALDH1A1 (0.56) TNKSPARP2OPRM1OPRD1OPRK1
SCHEMBL15289030 0.78 ALDH1A1 (0.56) TNKSPARP2OPRM1OPRD1OPRK1
SCHEMBL16455967 0.76 TNKS (0.54) TNKSPARP1PARP2OPRM1OGFRL1
SCHEMBL4627783 0.74 KDM1A (0.52) OPRM1OPRD1OPRK1OGFRL1KDM1A
SCHEMBL4814305 0.74 KDM1A (0.52) OPRM1OPRD1OPRK1OGFRL1KDM1A
SCHEMBL16997531 0.74 TNKS (0.57) TNKSPARP1PARP2HSD11B1KMT2A
SCHEMBL30531972 0.73 DRD2 (0.51) OPRM1OPRD1OPRK1OGFRL1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9505749-B2 Quinazolinone compounds and derivatives thereof AMGEN INC. (US) 2016-11-29 US disclosed
US-9505749-B2 Quinazolinone compounds and derivatives thereof AMGEN INC. (US) 2016-11-29 US disclosed
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof AMGEN INC. 2015-08-13 US disclosed
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof AMGEN INC. 2015-08-13 US disclosed
WO-2014036022-A1 QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. (US) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof TNKS, TPI1, TNKS1BP1 TNKS 1/4885PARP1 90/4885PARP2 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.